NCT01750827View on ClinicalTrials.gov

A Study to Assess the Effect of SB 659032 on Platelet Function

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions

Atherosclerosis

Interventions

DRUG

SB659032

single dose

Trial Locations (1)

66219

GSK Investigational Site, Lenexa

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01750827 - A Study to Assess the Effect of SB 659032 on Platelet Function | Biotech Hunter | Biotech Hunter